- Also known as
- Reta + Cagri · Retatrutide Cagrilintide blend · Reta Cagri · LY3437943 + cagrilintide
- Class
- Two-peptide research blend (GIP, GLP-1 and glucagon receptor agonist + long-acting amylin analogue)
- Form
- Lyophilised powder in 15 mg vials
- Sizes
- 15 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 15 mg: 3 mL
What is Retatrutide + Cagrilintide?
Retatrutide + Cagrilintide is a single vial holding Retatrutide 0 mg and Cagrilintide 0 mg as one lyophilised powder. The two are studied separately in the literature, and the studies cited on this page are those separate studies. Its sequence is recorded as Retatrutide (LY3437943) and cagrilintide in one vial; the mg split between them is still to be confirmed with the supplier. Published work on it is in human. 8 of the 8 studies listed below are controlled trials in people. We hold it as lyophilised powder in 15 mg vials; it is research material and nothing else. It is not a drug, and it is not supplied for use in a person or an animal.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Jastreboff AM et al.2023 · N Engl J Med · PMID 37366315 | Human, phase 2 randomised controlled trial in adults with obesity (n=338) | 1, 4, 8 or 12 mg once weekly, subcutaneous (4 and 8 mg arms started at 2 or 4 mg; 12 mg started at 2 mg), vs placebo | 48 weeks | Mean body weight change at 48 weeks was −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg) and −24.2% (12 mg) vs −2.1% with placebo. The most common adverse events were gastrointestinal, dose-related and mostly mild to moderate. |
| Bajaj HS et al.2026 · Lancet · PMID 42250575 | Human, phase 3 randomised controlled trial in adults with type 2 diabetes (n=537) | 4, 9 or 12 mg once weekly, subcutaneous, vs placebo | 40 weeks | HbA1c fell by 1.69%, 1.86% and 1.94% with 4, 9 and 12 mg vs 0.81% with placebo, and body weight changed by −11.5%, −13.9% and −15.3% vs −2.6%. Discontinuation for adverse events was 2–5% with retatrutide and 0% with placebo. |
| Sanyal AJ et al.2024 · Nat Med · PMID 38858523 | Human, phase 2a randomised controlled substudy in adults with MASLD and ≥10% liver fat (n=98) | 1, 4, 8 or 12 mg once weekly, subcutaneous, vs placebo | 48 weeks (liver fat primary endpoint at 24 weeks) | Mean relative change in liver fat at 24 weeks was −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg) and −82.4% (12 mg) vs +0.3% with placebo. |
| Urva S et al.2022 · Lancet · PMID 36354040 | Human, phase 1b randomised multiple-ascending dose trial in type 2 diabetes (n=72) | 0.5, 1.5, 3, 3/6 or 3/6/9/12 mg once weekly, subcutaneous, vs placebo or dulaglutide 1.5 mg | 12 weeks | Treatment-emergent adverse events were reported by 63% of participants on LY3437943, 60% on dulaglutide and 54% on placebo, with gastrointestinal disorders the most frequent. |
| Lau DCW et al.2021 · Lancet · PMID 34798060 | Human, phase 2 randomised controlled trial, cagrilintide alone, adults with overweight or obesity without diabetes (n=906 randomised: 706 cagrilintide, 99 liraglutide, 101 placebo) | Cagrilintide 0.3, 0.6, 1.2, 2.4 or 4.5 mg once weekly, subcutaneous; comparator liraglutide 3.0 mg once daily | 26 weeks treatment (including up to 6 weeks escalation), plus 6 weeks follow-up | Mean weight reduction was 6.0%–10.8% across the cagrilintide doses versus 3.0% with placebo. Cagrilintide 4.5 mg reduced weight by 10.8% compared with 9.0% for liraglutide 3.0 mg. |
| Gabe MBN et al.2024 · Diabetes Obes Metab · PMID 39279639 | Human, randomised double-blind thorough QT study, cagrilintide alone, healthy participants (n=105) | Cagrilintide once weekly subcutaneous, escalated to 4.5 mg; placebo arms received moxifloxacin 400 mg as a positive control | Not stated in the abstract | No clinically relevant QTcF prolongation occurred after the last 4.5 mg dose; the upper limits of the 90% confidence intervals of the placebo-adjusted changes were below 10 ms at all time points. |
| Frias JP et al.2023 · Lancet · PMID 37364590 | Human, phase 2 randomised double-blind trial, CagriSema (cagrilintide + semaglutide) vs semaglutide vs cagrilintide, type 2 diabetes on metformin (n=92) | CagriSema, semaglutide or cagrilintide, each escalated to 2.4 mg once weekly subcutaneous | 32 weeks | HbA1c fell by 2.2 points with CagriSema, 1.8 with semaglutide and 0.9 with cagrilintide alone. Body weight fell by 15.6%, 5.1% and 8.1% respectively. The partner drug in this trial was semaglutide, not retatrutide. |
| Garvey WT et al.2025 · N Engl J Med · PMID 40544433 | Human, phase 3a randomised controlled trial (REDEFINE 1), CagriSema vs each component vs placebo, adults with overweight or obesity without diabetes (n=3417) | Cagrilintide 2.4 mg + semaglutide 2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, once weekly | 68 weeks | Mean body weight change was −20.4% with CagriSema (cagrilintide with semaglutide) versus −3.0% with placebo. The abstract does not report the result for the cagrilintide-alone arm. |
What these studies don't show: There are controlled trials, though they answer narrow questions. Who was enrolled, what was measured and for how long all constrain what the results mean. None of it establishes safety outside the conditions each trial ran under. Testing establishes identity and purity; it is not evidence of an effect.
Every study links to its PubMed record. See all Retatrutide + Cagrilintide studies in the research library →
Retatrutide + Cagrilintide price in Canada: 15mg vial
Buy Retatrutide + Cagrilintide in Canada in a 15mg vial. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 15 mg | $104.00 | $6.93/mg |
Is Retatrutide + Cagrilintide available in Canada?
No product containing Retatrutide + Cagrilintide holds a Drug Identification Number in Canada. Nothing about its safety, efficacy or quality has been reviewed by a regulator here. Borealis Peptides supplies it for in-vitro laboratory research only, not for human or veterinary use. How Health Canada treats research peptides →
Side effects reported in studies
Each statement is tied to the study that reported it. Any tolerability finding below is quoted from the study that reported it. Human work of this size does not establish a safety profile.
Retatrutide + Cagrilintide FAQ
What is Retatrutide + Cagrilintide?
Retatrutide + Cagrilintide is a two-peptide research blend (GIP, GLP-1 and glucagon receptor agonist + long-acting amylin analogue), and that classification is where the published work starts. The published work on it is in human. Borealis Peptides supplies it as lyophilised powder in 15 mg vials for in-vitro laboratory research. Nothing here is a medicine; it is not for human or veterinary use. Below, every cited paper is shown with the system it used and what it found.
Where can I buy Retatrutide + Cagrilintide in Canada?
Direct from Borealis Peptides, held in Canadian stock so nothing crosses a border on its way to you. Stocked in 15 mg vials. Purity is confirmed by HPLC batch by batch, and we supply for laboratory research only. Each batch carries its own HPLC analysis, tied to the number printed on the vial.
Is Retatrutide + Cagrilintide legal in Canada?
No product containing Retatrutide + Cagrilintide holds a Drug Identification Number in Canada. Nothing about its safety, efficacy or quality has been reviewed by a regulator here. Borealis Peptides supplies it for in-vitro laboratory research only, not for human or veterinary use. Health Canada has said that "Research Use Only" labelling does not make a product legal to use in a person, so we treat it as a description of what the material is supplied for rather than a permission. Lawful use in your own setting is yours to establish.
How much Retatrutide + Cagrilintide should I use?
There is none to give. Nothing on this site is a protocol, a schedule or a reconstitution volume. The amounts in the cited studies belong to those studies and to the models they ran in, and they are listed so the evidence can be weighed rather than taken on trust.
What human evidence is there for Retatrutide + Cagrilintide?
Of the 8 studies cited, 8 are controlled trials in people and the rest are animal or cell work. Each row names its model, the amount used and what the authors reported, so the weight of each study can be judged directly rather than through a summary.
How is Retatrutide + Cagrilintide stored?
Storage for the sealed vial is −20 °C, away from light and moisture. Solutions are held at 2–8 °C. Because the dry form is stable at room temperature, shipping needs no cold chain; refrigerate it when it arrives. Light and repeated warming do more damage than the journey.
How is the purity of Retatrutide + Cagrilintide confirmed?
Every batch is tested by HPLC before it is sold, and the certificate refers to the batch in your vial rather than to the product in general. Keeping that batch number with your records is what makes an observation reproducible later. Certificates are available on request.
How does Retatrutide + Cagrilintide compare with Retatrutide and Cagrilintide?
They are different compounds with different published records, and this site does not rank them. Retatrutide and Cagrilintide have 6 cited studies and 8 cited studies on their page against 8 here. What separates them is the published work, which both pages set out in full.
Compare with
Related compounds
Cagrilintide
Long-acting amylin analogue (amylin receptor agonist)
Add 2 more to save 4%
AOD-9604
Modified C-terminal fragment of human growth hormone
Add 2 more to save 4%